Vasculitis (overview)L95.8
Synonym(s)
DefinitionThis section has been translated automatically.
Inflammation of blood vessels caused by a characteristic, phased inflammatory process in the walls of various types of blood vessels, which leads to various clinically and/or histopathologically defined clinical and/or histopathological clinical pictures (clinical-pathological entities).
ClassificationThis section has been translated automatically.
The classification of vasculitis is unsatisfactory, as the aetiology and pathogenesis of this heterogeneous group of diseases is still poorly understood. In the following, various common classification systems are juxtaposed without prejudice.
In clinical dermatology in particular, historically based, predominantly descriptive diagnostic entities continue to be used, which are not readily reflected in the current classifications, but are of relevant use in everyday clinical practice. The classification that most closely reflects the dermatological entities is that of Sunderkötter et al:
-
Classification according to "primary" and "secondary" vasculitis. This classification is not always reproducible, especially as there are wide areas of overlap between the two:
- Primary vasculitis: The triggering cause remains unknown. The pathogenesis is based on an immunological "hypersensitivity reaction". Autoantibodies against neutrophil granulocytes and/or endothelial cells (ANCA/AECA) as well as immunohistologic examinations are necessary for clarification.
- Secondary vasculitis: vasculitis in the context of underlying diseases (e.g. infections, collagenoses, in rheumatoid arthritis(rheumatoid vasculitis), can also be triggered by numerous medications).
-
Classification according to immunological causes. A distinction is made between:
- ANCA-associated vasculitis(granulomatosis with polyangiitis (GPA); microscopic polyangiitis (MPA); eosinophilic granulomatosis with polyangiitis (E-GPA); special form: drug-induced ANCA-positive vasculitis)
- Immune complex vasculitis (leukocytoclastic vasculitis)
- Pauci-immune vasculitis
- T-cell-mediated granulomatous vasculitis.
-
Classification according to vessel size and type of inflammation:
- This classification divides the vasculitides according to objectifiable histopathological criteria, which take into account the size of the vessels (small, medium and large) and the type and composition of the infiltrate (e.g. the important criterion of leukocytoclasia). " Small vessels" are capillaries, arterioles and venules; "medium-sized vessels" refers to medium-sized arterial and venous vessels and"large vessels" to the aorta and its direct branches or their branches (e.g. temporal artery). Even with this morphological classification, there are imprecisions and overlaps, especially when clinical and histological entities are used synonymously. For example, leukocytoclastic vasculitis (LcV) is based on several clinical entities. The common feature of this group is the exclusively histologically detectable pathological substrate, namely vasculitis with the decay of neutrophilic leukocytes, leukocytoclasia. This classification is therefore ultimately unsatisfactory from a clinical point of view.
- Histopathological and immunological classification and assignment of clinical entities (based on Sunderkötter). It has been shown that the occurrence of IgA-containing immune complexes (detection by DIF) has a significant prognostic (rather unfavorable prognosis) and therapeutic significance.
-
Vasculitis of small vessels (cutaneous small vessel vasculitis [CSVV]):
- LcV, largely IgA-associated:
- Schönlein-Henoch purpura
- Infantile, acute, hemorrhagic edema (age < 2 years)
- LcV (non-IgA-associated)
- LcV (non-IgA-associated) - with/without systemic involvement.
-
Urticarial vasculitis:
- Normocomplementemic urticarial vasculitis
- Hypocomplementemic urticarial vasculitis.
- Serum sickness
- Vasculitis in essential cryoglobulinemia
- Other (special forms):
- Granuloma (eosinophilicum) faciei
- Erythema elevatum diutinum
- Septic vasculitis
- Purpura fulminans
- LcV with eosinophilia (entity questionable)
- LcV in collagenoses (SLE, scleroderma).
- LcV, largely IgA-associated:
-
Vasculitis of medium-sized vessels:
- Systemic (ANCA-positive) vasculitis:
- Granulomatosis with polyangiitis (Wegener's granulomatosis)
- Eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
- Polyarteritis nodosa (PAN) group:
- Polyarteritis nodosa, systemic
- Microscopic polyangiitis (polyarteritis nodosa microscopic)
- Polyarteritis nodosa, cutaneous
- Other:
- Nodular vasculitis (erythema induratum)
- Kawasaki syndrome.
- Systemic (ANCA-positive) vasculitis:
- Vasculitis of large vessels:
HistologyThis section has been translated automatically.
The histological classification of a vasculitic process is performed in 3 steps (Ratzinger et al. 2015):
- 1. overview magnification: differentiation between small and medium-sized vessels
- 2. medium magnification: definition of the vessels affected - capillaries vs. post-capillary venules, arteries vs. veins - .
- 3. high magnification: definition of the cell infiltrate (leukocytoclastic, granulomatous, other infiltrate). Note: Vasculitis is always accompanied by an infiltrate in the vascular wall.
DiagnosisThis section has been translated automatically.
TherapyThis section has been translated automatically.
TablesThis section has been translated automatically.
Trigger of secondary vasculitides
Drugs |
ASA, allopurinol, thiazides, sulfonamides, gold, non-steroidal anti-inflammatories, phenothiazines, pyrazolones, ketoconazole, tetracyclines, penicillins, metamizole, propylthiouracil |
Bacterial and viral infections |
streptococci, staphylococci, Neisseria meningitidis and gonorrhoeae, Escherichia coli, mycoplasmas, Mycobacterium tuberculosis, hepatitis B virus, herpes viruses, influenza virus, cytomegalovirus |
Fungal infections |
Candida albicans |
Protozoa |
Trypanosomes, Plasmodium malariae |
Worm infection |
Helminths |
Autoantigens |
Rheumatoid arthritis, lupus erythematosus visceralis, Sjögren's syndrome |
Malignancies |
Lymphomas, breast carcinoma, hair cell leukemia, rarely solid tumours |
Food and food additives (rare) |
Tartrazine (E 102) |
Idiopathic |
Unexplained genesis (in about 50% of patients) |
Clinical classification of primary vasculitides (Chapel Hill Consensus Conference)
Vessel type |
Disease |
Definition |
Large |
temporal arteritis |
Granulomatous arteritis of the aorta and its larger branches, especially the extracranial carotid branches. Pat. > 40 years. Often associated with polymyalgia rheumatica. |
Medium size |
panarteritis nodosa |
Necrotizing inflammation of the medium-sized or even small arteries. No glomerulonephritis. Vasculitis of the arterioles, venules and capillaries. |
Medium size |
Mucocutaneous lymph node syndrome (Kawasaki syndrome) |
Arteritis of the middle and small arteries. Often accompanied by mucocutaneous lymph node enlargement. Coronary arteries are often affected. Occurs mainly in childhood. |
Small |
Granulomatosis with polyangiitis |
Granulomatous inflammation of the respiratory tract with necrotizing vasculitis. |
Small |
Eosinophilic granulomatosis with polynagiitis (Churg-Strauss syndrome) |
Eosinophil-rich, granulomatous inflammation of the respiratory tract and necrotizing vasculitis |
Small |
Microscopic polyangiitis |
Necrotizing vasculitis of small vessels without immune deposits in situ. Usually associated with necrotising glomerulonephritis and pulmonary capillariitis. |
Small |
purpura rheumatica |
Vasculitis of the small vessels with mainly IgA-containing immune depots (skin, gastrointestinal tract and renal glomeruli). |
Vasculitis/Vasculitis allergica superficialis | ||
Small |
Cryoglobulinemic vasculitis |
Vasculitis of the small vessels with cryoglobulin deposits in situ and cryoglobulin in serum. Especially skin and glomerula are affected. |
Therapeutic strategies for vasculitis (after Fiorentino)
Disease |
first-line therapy |
Level of evidence |
second-line therapy |
Level of evidence |
Third-line therapy |
Level of evidence |
Cutaneous vasculitis of small vessels |
NSAID |
D |
Antimalarials |
D |
Elimination diet |
D |
Colchicine | ||||||
AZA |
D |
|||||
C | ||||||
IVIG |
E |
|||||
ASA |
D |
|||||
CyA |
E |
|||||
Dapson |
D |
|||||
MTX |
E |
|||||
H1/H2 blocker |
D |
|||||
CYC |
E |
|||||
C | ||||||
PEX |
E |
|||||
CS | ||||||
| ||||||
Vasculitis with cryoglobulinemia (HCV negative) |
CS |
D |
Colchicine |
C |
IVIG |
E |
Chlorambucil |
E |
|||||
CYC |
D |
Melphalan |
E |
|||
Elimination diet |
A |
PEX (renal) |
D |
AZA |
E |
|
IFN alfa |
E |
CyA |
E |
|||
| ||||||
Vasculitis in cryoglobulinemia (HCV-positive) |
HCV therapy according to guidelines; monotherapy is obsolete |
A |
Ribavirin +/- IFN alfa |
C |
Colchicine |
C |
CYC +/- CS +/- PEX |
D |
|||||
| ||||||
Urticaria vasculitis |
H1/H2 blocker |
D |
AZA |
D |
CyA (HUVS) |
E |
Indomethacin |
D |
|||||
Dapsone (+/- pentoxifylline) |
C |
|||||
Colchicine |
C |
|||||
Antimalarials |
D |
|||||
CS (HUVS) (+/-cytotoxic agent) |
D |
|||||
| ||||||
Purpura Beautiful Enoch |
Rest, bed rest |
|
CS (prevents GN) |
A |
Factor XIII |
B |
CS + AZA (treatment of GN) |
C |
|||||
PEX (council RPGN) |
C |
|||||
CS + CYC (treatment of RPGN) |
D |
|||||
Ranitidine |
C |
|||||
CS |
C |
|||||
IVIG |
E |
|||||
Dapson |
D |
|||||
| ||||||
Microscopic polyangiitis (HBV negative) |
PEX + Vidarabine (+ CS) |
B |
CS + PEX |
B |
IVIG |
E |
PEX + IFN alfa-2b (+ CS) |
C |
|||||
B | ||||||
CS + PEX + CYC | ||||||
Microscopic polyangiitis |
CYC + CS (FFS > 2) |
B |
AZA +/-CS (MPA/CSS) |
D |
Kidney transplantation (MPA) |
E |
| ||||||
Eosinophilic granulomatosis with polyangiitis |
CS (FFS < 2) |
B |
IVIG (MPA/CSS) |
C |
|
|
IFN alfa |
E |
|||||
| ||||||
Panarteritis nodosa cutanea bengina |
NSAIDs |
D |
CS |
C |
Sulfapyridine (for IBD) |
E |
ASA |
D |
IVIG |
E |
|||
Pentoxifylline |
|
|||||
Penicillin (for streptococcus infection) |
D |
MTX |
E |
|||
| ||||||
Granulomatosis with polyangiitis (untreated) |
CYC + CS (FFS > 2) |
B |
PEX (renal) |
B |
MYC |
C |
TMP-SMX (nasal only) | ||||||
C | ||||||
MTX + CS |
B |
IVIG |
D |
|||
C | ||||||
AZA (limited form) | ||||||
Granulomatosis with polyangiitis (course) |
AZA + CS |
A |
CYC + CS |
B |
MYC |
C |
CyA | ||||||
D | ||||||
MTX +/- CS |
B |
TMP-SMX |
A |
|||
C | ||||||
Leflunomide | ||||||
Granulomatosis with polyangiitis (recurrence) |
CYC + CS |
C |
IVIG |
B |
ATG |
D |
Anti-CD4/CD52 |
D |
|||||
anti-CD20 |
E |
|||||
CyA |
D |
|||||
MYC |
C |
|||||
IFN alfa |
|
|||||
Thalidomide |
|
|||||
Etoposide |
|
|||||
15-deoxyspergualin |
D |
|||||
| ||||||
Collagenosis |
CS (mild form) |
C |
CYC + CS |
D |
Dapson |
E |
CYC + CS + PGE1 |
E |
|||||
Minocycline |
E |
|||||
MTX + CS |
D |
|||||
iloprost |
D |
|||||
AZA + CS |
D |
|||||
Penicillamine |
D |
|||||
PEX (renal) |
D |
|||||
Level of evidence: A: Double-blind, randomized, controlled study; B: Clinical study with > 20 patients (without control group); C: Clinical study with < 20 patients, case reports (> 20 patients), retrospective data analysis; D: Case reports with > 5 patients; E: Case reports with < 5 patients | ||||||
Abbreviations: NSAR = non-steroidal anti-inflammatory drugs; ASA = aspirin; AZA = azathioprine; CS = corticosteroids; Cya = ciclosporin A; CYC = cyclophosphamide; FFS = five factor score; HBV = hepatitis B virus; HCV = hepatitis C virus; HUVS = hypocomplementary urticaria vasculitis syndrome; IFN alfa = interferon alfa; IVIG = intravenous immunoglobulins; MTX = methotrexate; PEX = plasma exchange; TMP-SMX = trimethoprim-sulfamethoxazole; ATG = antithymocyte globulin |
Algorithm for diagnostic clarification in vasculitis (modified according to Fiorentino)
Clinical question or symptomatology |
yes/no |
Suspected diagnosis or parameters |
yes/no |
Suspected diagnosis or parameters |
yes/no |
Suspected diagnosis or parameters |
yes/no |
Suspected diagnosis or parameters |
Leucocytoclastic vasculitis ? |
yes |
Vasculitis-like diseases (e.g. vasculopathy) |
|
|
|
|
|
|
no |
|
|
|
|
|
|
|
|
Any signs of sepsis? |
yes |
Septic vasculitis |
|
|
|
|
|
|
no |
|
|
|
|
|
|
|
|
Cryoglobulins? |
yes |
Vasculitis with cryoglobulinemia |
|
|
|
|
|
|
no |
|
|
|
|
|
|
|
|
Vascular IgA? |
yes |
Purpura Beautiful Enoch |
|
|
|
|
|
|
no |
|
|
|
|
|
|
|
|
Urticaria? |
yes |
low C3/C4? |
yes |
Anti-C1q? |
yes |
Systemic lupus erythematosus? |
yes |
Vasculitis in collagenosis |
|
|
no |
|
no |
|
no |
|
|
no |
|
Normocomplementary urticarial vasculitis |
|
Hypocomplementary urticarial vasculitis |
|
Hypocomplementary urticarial vasculitis syndrome |
|
|
Collagenosis? |
yes |
|
|
|
|
|
|
|
no |
|
|
|
|
|
|
|
|
Malignant disease? |
yes |
Vasculitis in malignant disease |
|
|
|
|
|
|
no |
|
|
|
|
|
|
|
|
System participation? |
yes |
ANCA? |
yes |
Granulomatous inflammation? |
yes |
Asthma and/or eosinophilia? |
yes |
Churg-Strauss Syndrome |
|
|
|
no |
Microscopic polyangiitis |
|
Wegener's granulomatosis
|
|
|
|
no |
Signs of microscopic polyangiitis? |
|
|
|
|
|
|
|
|
no |
|
|
|
|
|
|
|
|
Non-classified vasculitis |
|
|
|
|
|
|
Livedo/subcutaneous nodules/sacral gangrene? |
yes |
Panarteritis nodosa cutanea bengina |
|
|
|
|
|
|
no |
|
|
|
|
|
|
|
|
Cutaneous vasculitis of small vessels (immune complex vasculitis) |
|
|
|
Note(s)This section has been translated automatically.
Phlebitides as vascular wall inflammations of larger trunk and extremity veins are also "vasculitides". However, they do not belong to the vasculitides listed here in the narrower sense. This also applies to endangiitis obliterans, which, as an independent vasculitic clinical picture with obligatory occlusive symptoms, is rather classified as an arterial occlusive disease. In many classifications, the term " vasculopathy" is also used, a general term for primarily non-inflammatory vascular diseases associated with partial or complete occlusion of a vessel (e.g., livedo racemosa). Because vasculitides of the skin organ are often associated with focal hemorrhage, the descriptive term "purpura" (e.g., Schönlein-Henoch purpura, anaphylactoid purpura, et al.) has been used in previous literature as a clinical diagnosis for an underlying "hemorrhagic leukocytoclastic vasculitis." The term"purpura" contains a vagueness dictated by history that we will not correct here.
LiteratureThis section has been translated automatically.
- Baigrie D et al (2022) Leukocytoclastic vasculitis. 2022 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing PMID: 29489227.
- Chen KR et al (2002) Clinical and histopathological spectrum of cutaneous vasculitis in rheumatoid arthritis. Br J Dermatol 147: 905-913.
- Crowson AN et al (2003) Cutaneous vasculitis: a review. J Cutan Pathol 30: 161-173.
- Fiorentino DF (2003) Cutaneous vasculitis. J Am Acad Dermatol 48: 311-340.
- Gibson LE (2001) Cutaneous vasculitis update. Dermatol Clin 19: 603-615
- Makol A et al (2015) Rheumatoid vasculitis: an update. Curr Opin Rheumatol 27:63-70.
- Muller CSL et al (2016) Diagnosis and histologic features of cutaneous vasculitides/vasculopathies. Act Dermatol 42: 286-301
- Sundkötter et al (2004) Leukocytoclastic vasculitis. Dermatol 55: 759-783
- Wiik A (2005) Clinical and laboratory characteristics of drug-induced vasculitic syndromes. Arthritis Res Ther 7: 191-192.